Search

Your search keyword '"Lai, Chih-Yun"' showing total 18 results
Start Over Author "Lai, Chih-Yun" Publication Year Range Last 10 years
18 results on '"Lai, Chih-Yun"'

1. Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80–Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates

Author

Preston, Kendall B., Wong, Teri Ann S., Lieberman, Michael M., To, Albert, Lai, Chih-Yun, Granados, Alex, Thomasson, Holly, Misamore, John, Yalley-Ogunro, Jake, Cabus, Mehtap, Andersen, Hanne, Donini, Oreola, Lehrer, Axel T., and Randolph, Theodore W.

Published
2022
Full Text
View/download PDF

3. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, Wongwiwat, Wiyada, Supasa, Sunpetchuda, Zhang, Xiaokang, Dai, Xinghong, Rouvinski, Alexander, Jumnainsong, Amonrat, Edwards, Carolyn, Quyen, Nguyen Than Ha, Duangchinda, Thaneeya, Grimes, Jonathan M, Tsai, Wen-Yang, Lai, Chih-Yun, Wang, Wei-Kung, Malasit, Prida, Farrar, Jeremy, Simmons, Cameron P, Zhou, Z Hong, Rey, Felix A, Mongkolsapaya, Juthathip, and Screaton, Gavin R

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Vaccine Related, Prevention, Infectious Diseases, Immunization, Biotechnology, Rare Diseases, Vector-Borne Diseases, Biodefense, Emerging Infectious Diseases, Infection, Good Health and Well Being, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Biological Assay, Cell Line, Dengue, Dengue Virus, Enzyme-Linked Immunosorbent Assay, Humans, Immunoblotting, Viral Envelope Proteins, Biochemistry and cell biology
Abstract

Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.

Published
2015

6. A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant

Author

To, Albert, primary, Wong, Teri Ann S., additional, Lieberman, Michael M., additional, Thompson, Karen, additional, Ball, Aquena H., additional, Pessaint, Laurent, additional, Greenhouse, Jack, additional, Daham, Nisrine, additional, Cook, Anthony, additional, Narvaez, Brandon, additional, Flinchbaugh, Zack, additional, Van Ry, Alex, additional, Yalley-Ogunro, Jake, additional, Andersen Elyard, Hanne, additional, Lai, Chih-Yun, additional, Donini, Oreola, additional, and Lehrer, Axel T., additional

Published
2022
Full Text
View/download PDF

7. Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1

Author

To, Albert, primary, Wong, Teri Ann S., additional, Lieberman, Michael M., additional, Thompson, Karen, additional, Pessaint, Laurent, additional, Greenhouse, Jack, additional, Daham, Nisrine, additional, Cook, Anthony, additional, Narvaez, Brandon, additional, Flinchbaugh, Zack, additional, Ry, Alex Van, additional, Yalley-Ogunro, Jake, additional, Elyard, Hanne Andersen, additional, Lai, Chih-Yun, additional, Donini, Oreola, additional, and Lehrer, Axel T., additional

Published
2021
Full Text
View/download PDF

8. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

Author

Lai, Chih-Yun, primary, To, Albert, additional, Wong, Teri Ann S., additional, Lieberman, Michael M., additional, Clements, David E., additional, Senda, James T., additional, Ball, Aquena H., additional, Pessaint, Laurent, additional, Andersen, Hanne, additional, Donini, Oreola, additional, and Lehrer, Axel T., additional

Published
2021
Full Text
View/download PDF

11. Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice

Author

To, Albert, primary, Medina, Liana O., additional, Mfuh, Kenji O., additional, Lieberman, Michael M., additional, Wong, Teri Ann S., additional, Namekar, Madhuri, additional, Nakano, Eileen, additional, Lai, Chih-Yun, additional, Kumar, Mukesh, additional, Nerurkar, Vivek R., additional, and Lehrer, Axel T., additional

Published
2018
Full Text
View/download PDF

13. Erratum: Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, primary, Wongwiwat, Wiyada, additional, Supasa, Sunpetchuda, additional, Zhang, Xiaokang, additional, Dai, Xinghong, additional, Rouvinsky, Alexander, additional, Jumnainsong, Amonrat, additional, Edwards, Carolyn, additional, Quyen, Nguyen Than Ha, additional, Duangchinda, Thaneeya, additional, Grimes, Jonathan M, additional, Tsai, Wen-Yang, additional, Lai, Chih-Yun, additional, Wang, Wei-Kung, additional, Malasit, Prida, additional, Farrar, Jeremy, additional, Simmons, Cameron P, additional, Zhou, Z Hong, additional, Rey, Felix A, additional, Mongkolsapaya, Juthathip, additional, and Screaton, Gavin R, additional

Published
2015
Full Text
View/download PDF

14. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

Author

Dejnirattisai, Wanwisa, primary, Wongwiwat, Wiyada, additional, Supasa, Sunpetchuda, additional, Zhang, Xiaokang, additional, Dai, Xinghong, additional, Rouvinski, Alexander, additional, Jumnainsong, Amonrat, additional, Edwards, Carolyn, additional, Quyen, Nguyen Than Ha, additional, Duangchinda, Thaneeya, additional, Grimes, Jonathan M, additional, Tsai, Wen-Yang, additional, Lai, Chih-Yun, additional, Wang, Wei-Kung, additional, Malasit, Prida, additional, Farrar, Jeremy, additional, Simmons, Cameron P, additional, Zhou, Z Hong, additional, Rey, Felix A, additional, Mongkolsapaya, Juthathip, additional, and Screaton, Gavin R, additional

Published
2014
Full Text
View/download PDF

16. Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Author

Dejnirattisai, Wanwisa, Wongwiwat, Wiyada, Supasa, Sunpetchuda, Zhang, Xiaokang, Dai, Xinghong, Rouvinsky, Alexander, Jumnainsong, Amonrat, Edwards, Carolyn, Quyen, Nguyen Than Ha, Duangchinda, Thaneeya, Grimes, Jonathan M, Tsai, Wen-Yang, Lai, Chih-Yun, Wang, Wei-Kung, Malasit, Prida, Farrar, Jeremy, Simmons, Cameron P, Zhou, Z Hong, Rey, Felix A, and Mongkolsapaya, Juthathip

Subjects
PUBLISHED errata, IMMUNOGLOBULINS, VIREMIA, DENGUE viruses, PERIODICAL publishing, PUBLISHING
Published
2015
Full Text
View/download PDF

17. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.

Author

Lai CY, To A, Wong TAS, Lieberman MM, Clements DE, Senda JT, Ball AH, Pessaint L, Andersen H, Donini O, and Lehrer AT

Abstract

The speed at which several COVID-19 vaccines went from conception to receiving FDA and EMA approval for emergency use is an achievement unrivaled in the history of vaccine development. Mass vaccination efforts using the highly effective vaccines are currently underway to generate sufficient herd immunity and reduce transmission of the SARS-CoV-2 virus. Despite the most advanced vaccine technology, global recipient coverage, especially in resource-poor areas remains a challenge as genetic drift in naïve population pockets threatens overall vaccine efficacy. In this study, we described the production of insect-cell expressed SARS-CoV-2 spike protein ectodomain and examined its immunogenicity in mice. We demonstrated that, when formulated with CoVaccine HT™adjuvant, an oil-in-water nanoemulsion compatible with lyophilization, our vaccine candidates elicit a broad-spectrum IgG response, high neutralizing antibody titers, and a robust, antigen-specific IFN-γ secreting response from immune splenocytes in outbred mice. Our findings lay the foundation for the development of a dry-thermostabilized vaccine that is deployable without refrigeration.

Published
2021
Full Text
View/download PDF

18. CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation.

Author

Haun BK, Lai CY, Williams CA, Wong TA, Lieberman MM, Pessaint L, Andersen-Elyard H, and Lehrer AT

Abstract

The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralising antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results